218 related articles for article (PubMed ID: 35754317)
1. Salivary metabolomics with machine learning for colorectal cancer detection.
Kuwabara H; Katsumata K; Iwabuchi A; Udo R; Tago T; Kasahara K; Mazaki J; Enomoto M; Ishizaki T; Soya R; Kaneko M; Ota S; Enomoto A; Soga T; Tomita M; Sunamura M; Tsuchida A; Sugimoto M; Nagakawa Y
Cancer Sci; 2022 Sep; 113(9):3234-3243. PubMed ID: 35754317
[TBL] [Abstract][Full Text] [Related]
2. Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination.
Murata T; Yanagisawa T; Kurihara T; Kaneko M; Ota S; Enomoto A; Tomita M; Sugimoto M; Sunamura M; Hayashida T; Kitagawa Y; Jinno H
Breast Cancer Res Treat; 2019 Oct; 177(3):591-601. PubMed ID: 31286302
[TBL] [Abstract][Full Text] [Related]
3. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
4. Multiple-matrix metabolomics analysis for the distinct detection of colorectal cancer and adenoma.
Zhang Y; Ni M; Tao Y; Shen M; Xu W; Fan M; Shan J; Cheng H
Metabolomics; 2024 Apr; 20(3):47. PubMed ID: 38642214
[TBL] [Abstract][Full Text] [Related]
5. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
6. [Proton nuclear magnetic resonance spectroscopy recognition of metabolic patterns in fecal extracts for early diagnosis of colorectal cancer].
Lin Y; Wang ZN; Ma CC; Liu CK; Yang JR; Shen ZW; Wu RH
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Sep; 50(9):788-793. PubMed ID: 27655598
[No Abstract] [Full Text] [Related]
7. Salivary metabolomic biomarkers for non-invasive lung cancer detection.
Kajiwara N; Kakihana M; Maeda J; Kaneko M; Ota S; Enomoto A; Ikeda N; Sugimoto M
Cancer Sci; 2024 May; 115(5):1695-1705. PubMed ID: 38417449
[TBL] [Abstract][Full Text] [Related]
8. Identification of salivary metabolomic biomarkers for oral cancer screening.
Ishikawa S; Sugimoto M; Kitabatake K; Sugano A; Nakamura M; Kaneko M; Ota S; Hiwatari K; Enomoto A; Soga T; Tomita M; Iino M
Sci Rep; 2016 Aug; 6():31520. PubMed ID: 27539254
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.
Chen F; Dai X; Zhou CC; Li KX; Zhang YJ; Lou XY; Zhu YM; Sun YL; Peng BX; Cui W
Gut; 2022 Jul; 71(7):1315-1325. PubMed ID: 34462336
[TBL] [Abstract][Full Text] [Related]
10. Urinary Polyamine Biomarker Panels with Machine-Learning Differentiated Colorectal Cancers, Benign Disease, and Healthy Controls.
Nakajima T; Katsumata K; Kuwabara H; Soya R; Enomoto M; Ishizaki T; Tsuchida A; Mori M; Hiwatari K; Soga T; Tomita M; Sugimoto M
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518931
[TBL] [Abstract][Full Text] [Related]
11. Urinary charged metabolite profiling of colorectal cancer using capillary electrophoresis-mass spectrometry.
Udo R; Katsumata K; Kuwabara H; Enomoto M; Ishizaki T; Sunamura M; Nagakawa Y; Soya R; Sugimoto M; Tsuchida A
Sci Rep; 2020 Dec; 10(1):21057. PubMed ID: 33273632
[TBL] [Abstract][Full Text] [Related]
12. UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer.
Wang X; Guan X; Tong Y; Liang Y; Huang Z; Wen M; Luo J; Chen H; Yang S; She Z; Wei Z; Zhou Y; Qi Y; Zhu P; Nong Y; Zhang Q
BMC Cancer; 2024 May; 24(1):644. PubMed ID: 38802800
[TBL] [Abstract][Full Text] [Related]
13. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
14. Salivary metabolites are promising noninvasive biomarkers of drug-induced liver injury.
Yu SM; Zheng HC; Wang SC; Rong WY; Li P; Jing J; He TT; Li JH; Ding X; Wang RL
World J Gastroenterol; 2024 May; 30(18):2454-2466. PubMed ID: 38764769
[TBL] [Abstract][Full Text] [Related]
15. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X
Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer Detection Using Targeted LC-MS Metabolic Profiling.
Djukovic D; Zhang J; Raftery D
Methods Mol Biol; 2018; 1765():229-240. PubMed ID: 29589312
[TBL] [Abstract][Full Text] [Related]
17. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.
Komor MA; Bosch LJ; Coupé VM; Rausch C; Pham TV; Piersma SR; Mongera S; Mulder CJ; Dekker E; Kuipers EJ; van de Wiel MA; Carvalho B; Fijneman RJ; Jimenez CR; Meijer GA; de Wit M
J Pathol; 2020 Mar; 250(3):288-298. PubMed ID: 31784980
[TBL] [Abstract][Full Text] [Related]
18. Integrated Analysis of Colorectal Cancer Reveals Cross-Cohort Gut Microbial Signatures and Associated Serum Metabolites.
Gao R; Wu C; Zhu Y; Kong C; Zhu Y; Gao Y; Zhang X; Yang R; Zhong H; Xiong X; Chen C; Xu Q; Qin H
Gastroenterology; 2022 Oct; 163(4):1024-1037.e9. PubMed ID: 35788345
[TBL] [Abstract][Full Text] [Related]
19. Tissue amino acid profile could be used to differentiate advanced adenoma from colorectal cancer.
Gao P; Zhou C; Zhao L; Zhang G; Zhang Y
J Pharm Biomed Anal; 2016 Jan; 118():349-355. PubMed ID: 26595283
[TBL] [Abstract][Full Text] [Related]
20. Global and targeted serum metabolic profiling of colorectal cancer progression.
Long Y; Sanchez-Espiridion B; Lin M; White L; Mishra L; Raju GS; Kopetz S; Eng C; Hildebrandt MAT; Chang DW; Ye Y; Liang D; Wu X
Cancer; 2017 Oct; 123(20):4066-4074. PubMed ID: 28640361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
